Granite Global Ventures

Granite Bio is a clinical-stage biotechnology company focused on developing first-in-class antibody therapies for inflammatory, autoimmune, and fibrotic diseases. The company's lead asset, GRT-001, is a monoclonal antibody designed to selectively deplete pathogenic pro-inflammatory monocytes while sparing tissue-resident macrophages, currently being evaluated in Phase 1 trials for inflammatory bowel disease. Its second program, GRT-002, targets interleukin-3 (IL-3) to address autoimmune inflammation and type II inflammation-driven conditions such as itch and allergies. Headquartered in Basel, Switzerland, Granite Bio is backed by a prominent syndicate of healthcare investors including Versant Ventures, Novartis Venture Fund, Forbion, and Sanofi Ventures.